Authors: Batist, G Welles, L

Citation: G. Batist et L. Welles, Developing drugs to decrease the toxicity of chemotherapy - In reply, J CL ONCOL, 19(14), 2001, pp. 3440-3441

Authors: Dai, F Kelley, JA Zhang, HP Malinowski, N Kavlick, MF Lietzau, J Welles, L Yarchoan, R Ford, H

Citation: F. Dai et al., Fluorometric determination of 2 '-beta-fluoro-2 ',3 '-dideoxyadenosine 5 '-triphosphate, the active metabolite of a new anti-human immunodeficiency virus drug, in human lymphocytes, ANALYT BIOC, 288(1), 2001, pp. 52-61

Authors: Little, RF Wyvill, KM Pluda, JM Welles, L Marshall, V Figg, WD Newcomb, FM Tosato, G Feigal, E Steinberg, SM Whitby, D Goedert, JJ Yarchoan, R

Citation: Rf. Little et al., Activity of thalidomide in AIDS-related Kaposis's sarcoma, J CL ONCOL, 18(13), 2000, pp. 2593-2602

Authors: Shapiro, CL Ervin, T Welles, L Azarnia, N Keating, J Hayes, DF

Citation: Cl. Shapiro et al., Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer, J CL ONCOL, 17(5), 1999, pp. 1435-1441